Artificial Intelligence Tool May Help Predict Heart Attacks

Cedars-Sinai Scientists Developed an AI Algorithm to Measure Coronary Plaque Buildup

Artificial Intelligence Tool: Investigators from Cedars-Sinai have created an artificial intelligence-enabled tool that may make it easier to predict if a person will have a heart attack.

Artificial Intelligence Tool, described in The Lancet Digital Health, accurately predicted which patients would experience a heart attack in five years based on the amount and composition of plaque in arteries that supply blood to the heart.

Plaque buildup can cause arteries to narrow, which makes it difficult for blood to get to the heart, increasing the likelihood of a heart attack. A medical test called a coronary computed tomography angiography (CTA) takes 3D images of the heart and arteries and can give doctors an estimate of how much a patient’s arteries have narrowed. Until now, however, there has not been a simple, automated and rapid way to measure the plaque visible in the CTA images.

“Coronary plaque is often not measured because there is not a fully automated way to do it,” said Damini Dey, PhD, director of the quantitative image analysis lab in the Biomedical Imaging Research Institute at Cedars-Sinai and senior author of the study. “When it is measured, it takes an expert at least 25 to 30 minutes, but now we can use this program to quantify plaque from CTA images in five to six seconds.”

Dey and colleagues analyzed CTA images from 1,196 people who underwent a coronary CTA at 11 sites in Australia, Germany, Japan, Scotland and the United States. The investigators trained the AI algorithm to measure plaque by having it learn from coronary CTA images, from 921 people, that already had been analyzed by trained doctors.

The algorithm works by first outlining the coronary arteries in 3D images, then identifying the blood and plaque deposits within the coronary arteries. Investigators found the tool’s measurements corresponded with plaque amounts seen in coronary CTAs. They also matched results with images taken by two invasive tests considered to be highly accurate in assessing coronary artery plaque and narrowing: intravascular ultrasound and catheter-based coronary angiography.

Finally, the investigators discovered that measurements made by the AI algorithm from CTA images accurately predicted heart attack risk within five years for 1,611 people who were part of a multicenter trial called the SCOT-HEART trial.

“More studies are needed, but it’s possible we may be able to predict if and how soon a person is likely to have a heart attack based on the amount and composition of the plaque imaged with this standard test,” said Dey, who is also professor of Biomedical Sciences at Cedars-Sinai.

Dey and colleagues are continuing to study how well their AI algorithm quantifies plaque deposits in patients who undergo coronary CTA.

Funding: The study was funded by the National Heart, Lung, and Blood Institute under award number 1R01HL148787-01A1.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”